Bio-Rad Laboratories, Inc. Reports Third-Quarter Revenue Growth of More Than 9 Percent

HERCULES, CA--(Marketwire - November 01, 2011) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the third quarter ended September 30, 2011.

Third-quarter reported revenues were $516.5 million, up 9.5% compared to $471.5 million reported for the third quarter of 2010. On a currency-neutral basis, quarterly revenues increased 1.1% compared to the same period last year. Third-quarter gross margin increased to 57.3%, compared to 56.5% during the same quarter in 2010.

Net income attributable to Bio-Rad for the third quarter was $45.9 million, or $1.61 per share on a fully diluted basis versus $1.59 per share reported for the same period last year.

Year-to-date revenues grew by 9.3% to $1.5 billion compared to $1.4 billion for the first three quarters of 2010. Adjusting for the impact of currency, revenue growth was 3.4%.

Year-to-date net income attributable to Bio-Rad for 2011 was $119.0 million, or $4.18 per share on a fully diluted basis compared to $117.6 million, or $4.18 per share during the same period in 2010.

“While performance in the third-quarter shows good momentum and growth in many of our core product areas, we are feeling the impact of an uncertain economic environment in many of our markets abroad,” said Norman Schwartz, Bio-Rad President and Chief Executive Officer. “As we wrap up the year, we will carefully monitor these pressures on our global operation and look for new opportunities to grow our business.”

Life Science
The Life Science segment net sales for the third quarter were $171.5 million, up 11.9% compared to the same period last year. On a currency-neutral basis, Life Science segment sales increased by 5.1% compared to the third quarter of 2010. These results reflect strength of the segment’s electrophoresis and imaging product lines, which showed solid growth during the third quarter. Performance was also bolstered by the Company’s amplification products, several new product launches, as well as assays for the Bio-Plex® suspension array system, which can analyze up to 100 biomolecules in a single patient sample.

Clinical Diagnostics
Reported net sales for the Clinical Diagnostics segment in the third quarter rose to $341.3 million, up 8.4% compared to the same quarter last year. On a currency-neutral basis, sales were down 0.9%. Overall performance of the Clinical Diagnostics segment was negatively affected by economic challenges impacting worldwide healthcare markets, partially offset by continuing growth of our quality controls and BioPlex® 2200 product lines. In July, the Company announced that it had received FDA Premarket Application approval from the FDA for its fourth-generation HIV assay, the GS HIV Combo Ag/Ab EIA (enzyme immunoassay). The new assay detects both HIV antigens and HIV antibodies, offering earlier detection of HIV infections, including acute HIV infections.

Management will discuss these results in a conference call at 2 PM Pacific Time (5 PM Eastern Time) November 1, 2011. Interested parties may access the call by dialing 800-322-5044 (in the U.S.) or 617-614-4927 (international), access number 51248028.

A live webcast of the conference call may be accessed in the “Investor Relations” section of www.bio-rad.com. A replay of the call will be available at 888-286-8010 (in the U.S.) or 617-801-6888 (international), access number 19666335, for seven days following the call. The webcast of the call will be archived on the Bio-Rad site for on-demand replay for up to a year and may be accessed in the “Investor Relations” section of www.bio-rad.com.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The Company employs over 6,800 people globally and had revenues exceeding $1.9 billion in 2010. For more information, visit www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company’s risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

 Bio-Rad Laboratories, Inc. Condensed Consolidated Statements of Income (in thousands, except per share data) (UNAUDITED) Three Months Ended Nine Months Ended September 30, September 30, ------------------------ ------------------------ 2011 2010 2011 2010 ----------- ----------- ----------- ----------- Net sales $ 516,514 $ 471,502 $ 1,523,291 $ 1,393,398 Cost of goods sold 220,338 205,172 656,368 601,633 ----------- ----------- ----------- ----------- Gross profit 296,176 266,330 866,923 791,765 Selling, general and administrative expense 176,867 148,654 521,370 458,541 Research and development expense 45,387 42,874 136,327 126,999 ----------- ----------- ----------- ----------- Income from operations 73,922 74,802 209,226 206,225 Interest expense 12,341 14,400 41,148 43,169 Foreign exchange losses, net 6,346 2,749 12,132 3,546 Other (income) expense, net (538) (256) (5,907) (3,572) ----------- ----------- ----------- ----------- Income before income taxes 55,773 57,909 161,853 163,082 Provision for income taxes (9,911) (12,824) (43,031) (44,084) ----------- ----------- ----------- ----------- Net income including noncontrolling interests 45,862 45,085 118,822 118,998 Net loss (income) attributable to noncontrolling interests 35 (321) 162 (1,416) ----------- ----------- ----------- ----------- Net income attributable to Bio-Rad $ 45,897 $ 44,764 $ 118,984 $ 117,582 =========== =========== =========== =========== Basic earnings per share: Net income per share basic attributable to Bio-Rad $ 1.63 $ 1.62 $ 4.25 $ 4.26 =========== =========== =========== =========== Weighted average common shares - basic 28,072 27,697 27,997 27,616 =========== =========== =========== =========== Diluted earnings per share: Net income per share diluted attributable to Bio-Rad $ 1.61 $ 1.59 $ 4.18 $ 4.18 =========== =========== =========== =========== Weighted average common shares - diluted 28,456 28,103 28,454 28,110 =========== =========== =========== =========== 

 Bio-Rad Laboratories, Inc. Condensed Consolidated Balance Sheets (in thousands) September 30, December 31, 2011 2010 -------------- -------------- (UNAUDITED) Current assets: Cash and cash equivalents $ 671,028 $ 906,551 Restricted cash - 6,422 Short-term investments 239,174 118,636 Accounts receivable, net 375,031 387,996 Inventories, net 445,581 398,100 Other current assets 146,889 157,641 -------------- -------------- Total current assets 1,877,703 1,975,346 Property, plant and equipment, net 338,942 333,617 Goodwill, net 371,227 363,981 Purchased intangibles, net 180,228 203,881 Other assets 201,695 185,939 -------------- -------------- Total assets $ 2,969,795 $ 3,062,764 ============== ============== Current liabilities: Accounts payable $ 113,476 $ 113,440 Accrued payroll and employee benefits 120,167 131,381 Notes payable and current maturities of long-term debt 806 233,181 Income and other taxes payable 46,368 50,935 Other current liabilities 134,509 137,690 -------------- -------------- Total current liabilities 415,326 666,627 Long-term debt, net of current maturities 731,597 731,100 Other long-term liabilities 129,226 124,518 -------------- -------------- Total liabilities 1,276,149 1,522,245 Bio-Rad stockholders’ equity 1,693,149 1,536,696 Noncontrolling interests 497 3,823 -------------- -------------- Total stockholders’ equity 1,693,646 1,540,519 -------------- -------------- Total liabilities and stockholders’ equity $ 2,969,795 $ 3,062,764 ============== ============== 

 Bio-Rad Laboratories, Inc. Condensed Consolidated Statements of Cash Flows (in thousands) (UNAUDITED) Nine Months Ended September 30, 2011 2010 ------------- ------------- Cash flows from operating activities: Cash received from customers $ 1,508,934 $ 1,367,777 Cash paid to suppliers and employees (1,249,674) (1,143,699) Interest paid (46,086) (48,812) Income tax payments (38,029) (50,254) Other operating activities 6,094 509 ------------- ------------- Net cash provided by operating activities 181,239 125,521 Cash flows from investing activities: Payments for acquisitions and long-term investments (8,698) (88,694) Other investing activities (205,191) (75,716) ------------- ------------- Net cash used in investing activities (213,889) (164,410) Cash flows from financing activities: Long-term borrowings - 2,000 Payments on long-term borrowings (226,615) (5,441) Other financing activities 14,788 10,664 ------------- ------------- Net cash (used in) provided by financing activities (211,827) 7,223 Effect of foreign exchange rate changes on cash 8,954 12,368 ------------- ------------- Net decrease in cash and cash equivalents (235,523) (19,298) Cash and cash equivalents at beginning of period 906,551 649,938 ------------- ------------- Cash and cash equivalents at end of period $ 671,028 $ 630,640 ============= ============= Reconciliation of net income including noncontrolling interests to net cash provided by operating activities: Net income including noncontrolling interests $ 118,822 $ 118,998 Adjustments to reconcile net income including noncontrolling interests to net cash provided by operating activities: Depreciation and amortization 88,127 79,964 Changes in working capital (49,450) (73,589) Other 23,740 148 ------------- ------------- Net cash provided by operating activities $ 181,239 $ 125,521 ============= =============